Meme Karsinoma İn Situ
Özet
Memenin in situ karsinomu, meme duktus ve lobülleriyle sınırlı heterojen bir neoplastik lezyon grubunu temsil eder. Tarama mamografilerinin yaygınlaşması ile son yıllarda bu lezyonların sıklığı artmıştır ve şu anda yeni tanı konulan tüm meme kanserlerinin yaklaşık % 25'ini oluşturmaktadır. Meme in situ karsinomlu hastalar invaziv meme kanseri gelişimi açısından normal popülasyondan daha risklidir ve bu hastaların izlenmesindeki amaç hastalık nükslerinin ve ikinci primer meme kanserlerinin erken tanınması ve tedavisi, tedaviyle ilişkili komplikasyon ve yan etkilerin değerlendirilmesi ve metastatik hastalıkla uyumlu semptomların tespitidir. Meme karsinoma in situ tespit edilen hastaların takibinde tanıdan sonraki ilk 5 yıl her 6 ila 12 ayda bir ve 5 yıldan sonra yılda bir öykü, fizik muayene ve yıllık mamografi yapılmalıdır. Diğer laboratuvar testleri, görüntüleme yöntemleri ve tümör belirteçleri hastalığın nüksünü tespit etmede ve invaziv kanser teşhisi koymada yararlı bulunmamıştır.
Carcinoma in situ of the breast represents a heterogeneous group of neoplastic lesions confined to the breast ducts and lobules. The frequency of these lesions has increased in recent years with the widespread use of screening mammography and now accounts for approximately 25% of all newly diagnosed breast cancers. Patients with carcinoma in situ of the breast are at higher risk of developing invasive breast cancer than the normal population, and the aim of monitoring these patients is early recognition and treatment of disease recurrences and second primary breast cancers, evaluation of treatment-related complications and side effects, and detection of symptoms consistent with metastatic disease. In the follow-up of patients with carcinoma in situ of the breast, history, physical examination and annual mammography should be performed every 6 to 12 months for the first 5 years after diagnosis and annually after 5 years. Other laboratory tests, imaging modalities and tumor markers have not been found to be useful in detecting disease recurrence and diagnosing invasive cancer.
Referanslar
Cancer facts and figures 2023. American Cancer Society. Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html.
van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, Verschuur E, Lane J, Jonkers J, Rea DW, Wesseling J; PRECISION team. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019 Aug;121(4):285-292. doi: 10.1038/s41416-019-0478-6.
Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005 May 1;103(9):1778-84. doi: 10.1002/cncr.20979.
Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer. 1987 Dec;56(6):814-9. doi: 10.1038/bjc.1987.296.
Andersen JA. Lobular carcinoma in situ. A long-term follow-up in 52 cases. Acta Pathol Microbiol Scand A. 1974 Jul;82(4):519-33. PMID: 4853025.
Morrow M, Schnitt SJ, Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol. 2015 Apr;12(4):227-38. doi: 10.1038/nrclinonc.2015.8. Epub 2015 Jan 27. PMID: 25622978.
Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301. PMID: 9149887.
Margenthaler JA, Duke D, Monsees BS, Barton PT, Clark C, Dietz JR. Correlation between core biopsy and excisional biopsy in breast high-risk lesions. Am J Surg. 2006 Oct;192(4):534-7. doi: 10.1016/j.amjsurg.2006.06.003. PMID: 16978969.
Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, Pankratz VS, de Groen PC, Lingle WL, Ghosh K, Penheiter L, Tlsty T, Melton LJ 3rd, Reynolds CA, Hartmann LC. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007 Jul 1;25(19):2671-7. doi: 10.1200/JCO.2006.09.0217. Epub 2007 Jun 11. PMID: 17563394.
Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer. 2007 Jan 15;109(2):180-7. doi: 10.1002/cncr.22408. PMID: 17154175.
Liberman L, Cohen MA, Dershaw DD, Abramson AF, Hann LE, Rosen PP. Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy. AJR Am J Roentgenol. 1995 May;164(5):1111-3. doi: 10.2214/ajr.164.5.7717215. PMID: 7717215.
Liberman L, Dershaw DD, Rosen PP, Giess CS, Cohen MA, Abramson AF, Hann LE. Stereotaxic core biopsy of breast carcinoma: accuracy at predicting invasion. Radiology. 1995 Feb;194(2):379-81. doi: 10.1148/radiology.194.2.7824713. PMID: 7824713.
Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003 Jan 11;361(9352):125-9. doi: 10.1016/S0140-6736(03)12230-1. Erratum in: Lancet. 2003 Jun 7;361(9373):1994. PMID: 12531579.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Version 4.2024 — July 3, 2024 Continue NCCN.org
Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield MR, Davidson NE; American Society of Clinical Oncology. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006 Nov 1;24(31):5091-7. doi: 10.1200/JCO.2006.08.8575.
Ciatto S, Andreoli C, Cirillo A, Bonardi R, Bianchi S, Santoro G, Farante G, Magni A, Campa T, Costa A, et al. The risk of breast cancer subsequent to histologic diagnosis of benign intraductal papilloma follow-up study of 339 cases. Tumori. 1991 Feb 28;77(1):41-3. doi: 10.1177/030089169107700110.
Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985 Jan 17;312(3):146-51. doi: 10.1056/NEJM198501173120303. PMID: 3965932.
Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982 Feb15;49(4):751-8. doi: 10.1002/1097-0142(19820215)49:4<751::aid-cncr2820490426>3.0.co;2-y. PMID: 6275978.
London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992 Feb 19;267(7):941-4. Erratum in: JAMA 1992 Apr 1;267(13):1780. PMID: 1734106.
Is 'fibrocystic disease' of the breast precancerous? Arch Pathol Lab Med. 1986 Mar;110(3):171-3. PMID: 3606334.
Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer. 1990 Sep 15;66(6 Suppl):1326-35.doi:10.1002/1097-0142(19900915)66:14+<1326::aid-cncr2820661405>3.0.co;2-p. PMID: 2205361.
Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, Schuyler PA. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994 Jul 7;331(1):10-5. doi: 10.1056/NEJM199407073310103. PMID: 8202095.
Port ER, Park A, Borgen PI, Morris E, Montgomery LL. Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. Ann Surg Oncol. 2007 Mar;14(3):1051-7. doi: 10.1245/s10434-006-9195-5. Epub 2007 Jan 7.
Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG; Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004 Jul 29;351(5):427-37. doi: 10.1056/NEJMoa031759.
King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, Morrogh M, Sakr RA, Morrow M. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat. 2013 Nov;142(2):445-53. doi: 10.1007/s10549-013-2725-5.
